|
1
|
Mark PB, Stafford LK, Grams ME, Aalruz H,
ElHafeez SA, Abdelgalil AA, Abdulkader RS, Abeywickrama HM, Abiodun
OO, Abramov D, et al: Global, regional, and national burden of
chronic kidney disease in adults, 1990–2023, and its attributable
risk factors: A systematic analysis for the global burden of
disease study 2023. Lancet. 406:2461–2482. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zeisberg M and Neilson EG: Mechanisms of
tubulointerstitial fibrosis. J Am Soc Nephrol. 21:1819–1834. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Woroniecki R, Gaikwad AB and Susztak K:
Fetal environment, epigenetics, and pediatric renal disease.
Pediatr Nephrol. 26:705–711. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wing MR, Ramezani A, Gill HS, Devaney JM
and Raj DS: Epigenetics of progression of chronic kidney disease:
Fact or fantasy? Semin Nephrol. 33:363–374. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Buchanan S, Combet E, Stenvinkel P and
Shiels PG: Klotho, aging, and the failing kidney. Front Endocrinol
(Lausanne). 11:5602020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Satoh M, Nagasu H, Morita Y, Yamaguchi TP,
Kanwar YS and Kashihara N: Klotho protects against mouse renal
fibrosis by inhibiting Wnt signaling. Am J Physiol Renal Physiol.
303:F1641–F1651. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zeng Y, Wang PH, Zhang M and Du JR:
Aging-related renal injury and inflammation are associated with
downregulation of Klotho and induction of RIG-I/NF-κB signaling
pathway in senescence-accelerated mice. Aging Clin Exp Res.
28:69–76. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhao Y, Banerjee S, Dey N, LeJeune WS,
Sarkar PS, Brobey R, Rosenblatt KP, Tilton RG and Choudhary S:
Klotho depletion contributes to increased inflammation in kidney of
the db/db mouse model of diabetes via RelA (serine)536
phosphorylation. Diabetes. 60:1907–1916. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sun G, Reddy MA, Yuan H, Lanting L, Kato M
and Natarajan R: Epigenetic histone methylation modulates fibrotic
gene expression. J Am Soc Nephrol. 21:2069–2080. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu N, He S, Ma L, Ponnusamy M, Tang J,
Tolbert E, Bayliss G, Zhao TC, Yan H and Zhuang S: Blocking the
class I histone deacetylase ameliorates renal fibrosis and inhibits
renal fibroblast activation via modulating TGF-beta and EGFR
signaling. PLoS One. 8:e540012013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Singh BN, Zhang G, Hwa YL, Li J, Dowdy SC
and Jiang SW: Nonhistone protein acetylation as cancer therapy
targets. Expert Rev Anticancer Ther. 10:935–954. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pang M and Zhuang S: Histone deacetylase:
A potential therapeutic target for fibrotic disorders. J Pharmacol
Exp Ther. 335:266–272. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gilbert RE, Huang Q, Thai K, Advani SL,
Lee K, Yuen DA, Connelly KA and Advani A: Histone deacetylase
inhibition attenuates diabetes-associated kidney growth: Potential
role for epigenetic modification of the epidermal growth factor
receptor. Kidney Int. 79:1312–1321. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin W, Zhang Q, Liu L, Yin S, Liu Z and
Cao W: Klotho restoration via acetylation of peroxisome
proliferation-activated receptor γ reduces the progression of
chronic kidney disease. Kidney Int. 92:669–679. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang Y, Jiao B, Hu Z and Wang Y: Critical
role of histone deacetylase 3 in the regulation of kidney
inflammation and fibrosis. Kidney Int. 105:775–790. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen F, Zhang L, Liu W, Zhang B, Wang S,
Zhou Z, Wang W, Shen J, Deng Y and Cao W: Epigenetic suppression of
RASAL1 by HDAC3 and cofactor YY1 promotes fibroblast-myofibroblast
transition and renal fibrosis. Research (Wash D C).
9:10732026.PubMed/NCBI
|
|
17
|
Cui H, Guo M, Xu D, Ding ZC, Zhou G, Ding
HF, Zhang J, Tang Y and Yan C: The stress-responsive gene ATF3
regulates the histone acetyltransferase Tip60. Nat Commun.
6:67522015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhu J, Wang F, Wang L, Dai B, Xu G, Zhao
L, Jiang H, Gao W, Zhang T, Zhao C, et al: HDAC inhibition
increases CXCL12 secretion to recruit natural killer cells in
peripheral T-cell lymphoma. Cancer Res. 84:2450–2467. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nguyen HCB, Adlanmerini M, Hauck AK and
Lazar MA: Dichotomous engagement of HDAC3 activity governs
inflammatory responses. Nature. 584:286–290. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li HF, Cheng CF, Liao WJ, Lin H and Yang
RB: ATF3-mediated epigenetic regulation protects against acute
kidney injury. J Am Soc Nephrol. 21:1003–1013. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhu B, Ni Y, Gong Y, Kang X, Guo H, Liu X,
Li J and Wang L: Formononetin ameliorates ferroptosis-associated
fibrosis in renal tubular epithelial cells and in mice with chronic
kidney disease by suppressing the Smad3/ATF3/SLC7A11 signaling.
Life Sci. 315:1213312023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang L, Liu Y, Du T, Yang H, Lei L, Guo M,
Ding HF, Zhang J, Wang H, Chen X and Yan C: ATF3 promotes
erastin-induced ferroptosis by suppressing system Xc. Cell Death
Differ. 27:662–675. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tang Q, Xie J, Wang Y, Dong C and Sun Q:
Exosomes secreted by ATF3/Nrf2-mediated ferroptotic renal tubular
epithelial cells promote M1/M2 ratio imbalance inducing renal
interstitial fibrosis following ischemia and reperfusion injury.
Front Immunol. 16:15105002025. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Darlyuk-Saadon I, Weidenfeld-Baranboim K,
Yokoyama KK, Hai T and Aronheim A: The bZIP repressor proteins,
c-Jun dimerization protein 2 and activating transcription factor 3,
recruit multiple HDAC members to the ATF3 promoter. Biochim Biophys
Acta. 1819:1142–1153. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li J, Lin Q, Shao X, Li S, Zhu X, Wu J,
Mou S, Gu L, Wang Q, Zhang M, et al: HIF1α-BNIP3-mediated mitophagy
protects against renal fibrosis by decreasing ROS and inhibiting
activation of the NLRP3 inflammasome. Cell Death Dis. 14:2002023.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guan X, Nie L, He T, Yang K, Xiao T, Wang
S, Huang Y, Zhang J, Wang J, Sharma K, et al: Klotho suppresses
renal tubulo-interstitial fibrosis by controlling basic fibroblast
growth factor-2 signalling. J Pathol. 234:560–572. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang D, Li Z, Gao Y and Sun H: MiR-556-3p
mediated repression of klotho under oxidative stress promotes
fibrosis of renal tubular epithelial cells. Sci Rep. 15:121822025.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang Y and Zhao J: The protective function
of αKlotho in chronic kidney disease: Evidence and therapeutic
implications. Integr Med Nephrol Androl. 11:1–11. 2024. View Article : Google Scholar
|
|
30
|
Nan QY, Piao SG, Jin JZ, Chung BH, Yang CW
and Li C: Pathogenesis and management of renal fibrosis induced by
unilateral ureteral obstruction. Kidney Res Clin Pract. 43:586–599.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tang J and Zhuang S: Epigenetics in acute
kidney injury. Curr Opin Nephrol Hypertens. 24:351–358.
2015.PubMed/NCBI
|
|
32
|
Zhuang S: Epigenetic targeting for acute
kidney injury. Nephrology (Carlton). 23 (Suppl 4):S21–S25. 2018.
View Article : Google Scholar
|
|
33
|
Ji H, Zhou Y, Zhuang X, Zhu Y, Wu Z, Lu Y,
Li S, Zeng Y, Lu QR, Huo Y, et al: HDAC3 deficiency promotes liver
cancer through a defect in H3K9ac/H3K9me3 transition. Cancer Res.
79:3676–3688. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xie H, Miao N, Xu D, Zhou Z, Ni J, Yin F,
Wang Y, Cheng Q, Chen P, Li J, et al: FoxM1 promotes Wnt/β-catenin
pathway activation and renal fibrosis via transcriptionally
regulating multi-Wnts expressions. J Cell Mol Med. 25:1958–1971.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li SS, Sun Q, Hua MR, Suo P, Chen JR, Yu
XY and Zhao YY: Targeting the Wnt/β-catenin signaling pathway as a
potential therapeutic strategy in renal tubulointerstitial
fibrosis. Front Pharmacol. 12:7198802021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ma J, Jiao N, Liu X and Lu X: Saracatinib
delays the progression of renal interstitial fibrosis by inhibiting
the Wnt/β-catenin pathway. Kidney360. 7:25–34. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Izquierdo MC, Perez-Gomez MV, Sanchez-Niño
MD, Sanz AB, Ruiz-Andres O, Poveda J, Moreno JA, Egido J and Ortiz
A: Klotho, phosphate and inflammation/ageing in chronic kidney
disease. Nephrol Dial Transplant. 27 (Suppl 4):iv6–iv10. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cheikh Hassan HI, Tang M, Djurdjev O,
Langsford D, Sood MM and Levin A: Infection in advanced chronic
kidney disease leads to increased risk of cardiovascular events,
end-stage kidney disease and mortality. Kidney Int. 90:897–904.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chen C, Lin XH, Xie YM, Xiong SL, Hou SZ,
Huang S, Jian HL, Wen YF, Jiang XY and Liang J: Shengjiang Xiexin
Decoction ameliorates DSS-induced ulcerative colitis via activating
Wnt/β-Catenin signaling to enhance epithelium renovation and
modulating intestinal flora. Phytomedicine. 139:1564562025.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jia Y, Zheng Z, Guan M, Zhang Q, Li Y,
Wang L and Xue Y: Exendin-4 ameliorates high glucose-induced
fibrosis by inhibiting the secretion of miR-192 from injured renal
tubular epithelial cells. Exp Mol Med. 50:1–13. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xie L, Wang Y, Li Q, Ji X, Tu Y, Du S, Lou
H, Zeng X, Zhu L, Zhang J and Zhu M: The
HIF-1α/p53/miRNA-34a/Klotho axis in retinal pigment epithelial
cells promotes subretinal fibrosis and exacerbates choroidal
neovascularization. J Cell Mol Med. 25:1700–1711. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen K, Wang S, Sun QW, Zhang B, Ullah M
and Sun Z: Klotho deficiency causes heart aging via impairing the
Nrf2-GR pathway. Circ Res. 128:492–507. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yuan Q, Ren Q, Li L, Tan H, Lu M, Tian Y,
Huang L, Zhao B, Fu H, Hou FF, et al: A Klotho-derived peptide
protects against kidney fibrosis by targeting TGF-β signaling. Nat
Commun. 13:4382022. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hajare AD, Dagar N and Gaikwad AB: Klotho
antiaging protein: Molecular mechanisms and therapeutic potential
in diseases. Mol Biomed. 6:192025. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Nijhawan P: Soluble alpha klotho for
reversal of renal interstitial fibrosis and renal regeneration: A
hypothesis based on developmental biology and preclinical evidence:
TH-PO0573. J Am Soc Nephrol. 36((10S)): TH–PO0573. 2025.
|
|
46
|
Zhang Y, Zhang Q, Zhang Y and Han J: The
role of histone modification in DNA replication-coupled nucleosome
assembly and cancer. Int J Mol Sci. 24:49392023. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Xia J and Cao W: Epigenetic modifications
of Klotho expression in kidney diseases. J Mol Med (Berl).
99:581–592. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Xiong C, Guan Y, Zhou X, Liu L, Zhuang MA,
Zhang W, Zhang Y, Masucci MV, Bayliss G, Zhao TC and Zhuang S:
Selective inhibition of class IIa histone deacetylases alleviates
renal fibrosis. FASEB J. 33:8249–8262. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang L and Cao W: Histone deacetylase 3
(HDAC3) as an important epigenetic regulator of kidney diseases. J
Mol Med (Berl). 100:43–51. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chen F, Gao Q, Wei A, Chen X, Shi Y, Wang
H and Cao W: Histone deacetylase 3 aberration inhibits Klotho
transcription and promotes renal fibrosis. Cell Death Differ.
28:1001–1012. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhu B, Zhang L, Zhou X, Ning H and Ma T:
Transcription factor ZNF22 regulates blood-tumor barrier
permeability by interacting with HDAC3 protein. Front Mol Neurosci.
15:10279422022. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Jeon HB and Jang Y: Reversible
inactivation of bovine plasma amine oxidase by cysteamine and
related analogs. Biochem Biophys Res Commun. 403:442–446. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Sung CC, Poll BG, Lin SH,
Murillo-de-Ozores AR, Chou CL, Chen L, Yang CR, Chen MH, Hsu YJ and
Knepper MA: Early molecular events mediating loss of aquaporin-2
during ureteral obstruction in rats. J Am Soc Nephrol.
33:2040–2058. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Miao J, Liu J, Niu J, Zhang Y, Shen W, Luo
C, Liu Y, Li C, Li H, Yang P, et al: Wnt/β-catenin/RAS signaling
mediates age-related renal fibrosis and is associated with
mitochondrial dysfunction. Aging Cell. 18:e130042019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Guo Y, Zhuang X, Huang Z, Zou J, Yang D,
Hu X, Du Z, Wang L and Liao X: Klotho protects the heart from
hyperglycemia-induced injury by inactivating ROS and NF-κB-mediated
inflammation both in vitro and in vivo. Biochim Biophys Acta Mol
Basis Dis. 1864:238–251. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lai L, Li Y, Liu J, Luo L, Tang J, Xue J
and Liu T: Bovine serum albumin aggravates macrophage M1 activation
and kidney injury in heterozygous Klotho-deficient mice via the gut
microbiota-immune axis. Int J Biol Sci. 17:742–755. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Chun P: Histone deacetylase inhibitors in
medical therapeutics. Medical Epigenetics. Elsevier; pp. 633–655.
2016, View Article : Google Scholar
|
|
58
|
Li Y, Wang F, Chen X, Wang J, Zhao Y, Li Y
and He B: Zinc-dependent deacetylase (HDAC) inhibitors with
different zinc binding groups. Curr Top Med Chem. 19:223–241. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
El Omari N, Bakrim S, Elhrech H, Aanniz T,
Balahbib A, Lee LH, Al Abdulmonem W and Bouyahya A: Clinical
efficacy and mechanistic insights of FDA-approved HDAC inhibitors
in the treatment of lymphoma. Eur J Pharm Sci. 208:1070572025.
View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Cappellacci L, Perinelli DR, Maggi F,
Grifantini M and Petrelli R: Recent progress in histone deacetylase
inhibitors as anticancer agents. Curr Med Chem. 27:2449–2493. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Li J, Yu C, Shen F, Cui B, Liu N and
Zhuang S: Class IIa histone deacetylase inhibition ameliorates
acute kidney injury by suppressing renal tubular cell apoptosis and
enhancing autophagy and proliferation. Front Pharmacol.
13:9461922022. View Article : Google Scholar : PubMed/NCBI
|
